ClinicalTrials.gg
CompletedNCT06681441Updated Mar 25, 2025

A 3-way Cross-over Study on the Effects of QRL-101 on Transcranial Magnetic Stimulation and Nerve Excitability in Healthy Participants

A Phase 1 interventional study of QRL-101 Dose A and QRL-101 Dose B in Healthy, sponsored by QurAlis Corporation. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-25.

Sponsored by QurAlis Corporation · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a phase I, prospective, single-center, randomized, double-blind, placebo-controlled, three-way cross-over study to evaluate the safety and tolerability of QRL-101 and investigate the pharmacodynamic effects of two dose levels of QRL-101 on transcranial magnetic stimulation (TMS) and nerve excitability threshold tracking (NETT) in healthy participants.

After screening and training, participants will be randomized to one of six treatment sequences of William's square balanced for first-order carry-over design consisting of two doses of QRL-101 or placebo, with at least seven days between each treatment.

02

Conditions studied

  • Healthy

Keywords

  • QRL-101
03

In context

Lead sponsor

QurAlis Corporation is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and women between the ages ≥ 18 and ≤ 55.
  2. ≥ 18.0 and ≤ 32.0 kg/m2, and body weight ≥ 50 kg, at screening.
  3. Willing and able to practice effective from the screening through at least 2 days after their last dose of study treatment.
  4. Participants must be able to communicate effectively (in Dutch) with the study personnel and be willing to comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of any acute or chronic disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study.
  2. History or presence of conditions which, in the judgment of the investigator, are known to interfere with drug absorption, distribution, metabolism, or excretion.
  3. History or presence of conditions which might increase the risk of performing TMS (e.g., epilepsy, febrile seizures, intracranial mass lesion, hydrocephalus, head injury or trauma, metal objects in the brain or skull, cochlear implant or a deep brain stimulation device)
  4. Any condition that could interfere with the quality of, or ability to perform, TMS (e.g., an abnormal sleeping pattern, unremovable dreadlocks or hairpieces, or a resting motor threshold (rMT) of more than 75%.

*Other inclusion and exclusion criteria may apply*

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Treatment Group 1

    Participants will be randomized into 1 of 6 treatment sequences in a 3-way cross-over

    Drug: QRL-101 Dose A · Drug: QRL-101 Dose B · Drug: Placebo

  • Experimental
    Treatment Group 2

    Participants will be randomized into 1 of 6 treatment sequences in a 3-way cross-over

    Drug: QRL-101 Dose A · Drug: QRL-101 Dose B · Drug: Placebo

  • Experimental
    Treatment Group 3

    Participants will be randomized into 1 of 6 treatment sequences in a 3-way cross-over

    Drug: QRL-101 Dose A · Drug: QRL-101 Dose B · Drug: Placebo

  • Experimental
    Treatment Group 4

    Participants will be randomized into 1 of 6 treatment sequences in a 3-way cross-over

    Drug: QRL-101 Dose A · Drug: QRL-101 Dose B · Drug: Placebo

  • Experimental
    Treatment Group 5

    Participants will be randomized into 1 of 6 treatment sequences in a 3-way cross-over

    Drug: QRL-101 Dose A · Drug: QRL-101 Dose B · Drug: Placebo

  • Experimental
    Treatment Group 6

    Participants will be randomized into 1 of 6 treatment sequences in a 3-way cross-over

    Drug: QRL-101 Dose A · Drug: QRL-101 Dose B · Drug: Placebo

Interventions

  • All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.

  • All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.

  • DrugPlacebo

    All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.

06

What researchers measure

Primary outcomes

  1. Single pulse TMS-EMG motor evoked potential (MEP) amplitude (μV) compared to placebo

    To compare two dose levels of QRL-101 versus placebo on cortical excitability

    Time frame: 3 study periods, with a washout period of at least 7 days between each visit. Each study period consists of 2 nights and 1 study day.

  2. mNETT strength-duration time constant (SDTC) compared to placebo SDTC

    To compare two dose levels of QRL-101 versus placebo on peripheral motor nerve excitability

    Time frame: 3 study periods, with a washout period of at least 7 days between each visit. Each study period consists of 2 nights and 1 study day.

Secondary outcomes

  1. Other Single pulse TMS-EMG MEP parameters

    To compare two dose levels of QRL-101 versus placebo on cortical excitability

    Time frame: 3 study periods, with a washout period of at least 7 days between each visit. Each study period consists of 2 nights and 1 study day.

  2. pEEG: power in the alpha frequency bands in resting state with eyes open and closed

    To compare two dose levels of QRL-101 versus placebo on spontaneous brain activity measured by resting state pharmaco-encephalography (pEEG)

    Time frame: 3 study periods, with a washout period of at least 7 days between each visit. Each study period consists of 2 nights and 1 study day.

  3. Incidence of AEs and SAEs

    Absolute values and changes from baseline values in vital signs, clinical laboratory tests, and ECG parameters

    Time frame: 3 study periods, with a washout period of at least 7 days between each visit. Each study period consists of 2 nights and 1 study day.

  4. Plasma QRL-101 concentrations

    AUC0-24

    Time frame: 3 study periods, with a washout period of at least 7 days between each visit. Each study period consists of 2 nights and 1 study day.

07

Study locations

1 site
  • Centre for Human Drug Research
    Leiden, 2333, Netherlands
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Dec 2024, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2024
First posted
Nov 8, 2024
StartActual
Oct 7, 2024
Primary completionActual
Dec 24, 2024
CompletionActual
Dec 24, 2024
Last update
Mar 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06681441
Lead sponsor
QurAlis Corporation
Collaborators
Centre for Human Drug Research, Netherlands
Responsible party
Sponsor
First posted
Nov 8, 2024
Start date
Oct 7, 2024
Primary completion
Dec 24, 2024
Completion
Dec 24, 2024
Last update
Mar 25, 2025

Study contacts

Philip Kremer, PharmD, MD, PhD
principal investigator · Centre for Human Drug Research
K. (Kaye) de Cuba,, MD
principal investigator · Centre for Human Drug Research

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QRL-101

Start the discussion